Log on/register
BioMed Central home | Journals A-Z | Feedback | Support | My details
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.
Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD, Motzer RJ
J Transl Med 2007, 5:32
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]


printer friendly 
to  [Help]

PubMed Central articles that cite the above article:

1.
Phase II study of sunitinib in men with advanced prostate cancer.
Dror Michaelson M, Regan MM, Oh WK, Kaufman DS, Olivier K, Michaelson SZ, Spicer B, Gurski C, Kantoff PW, Smith MR
Ann Oncol 2009 May, 20:913-20
 [PubMed Central] [PubMed] [Related articles]
2.
Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.
Ebos JM, Lee CR, Kerbel RS
Clin Cancer Res 2009 Aug 15, 15:5020-5
 [PubMed Central] [PubMed] [Related articles]
3.
Treatment selection for patients with metastatic renal cell carcinoma.
Atkins MB, Choueiri TK, Cho D, Regan M, Signoretti S
Cancer 2009 May 15, 115(10 Suppl):2327-33
 [PubMed Central] [PubMed] [Related articles]
4.
Placental growth factor (PlGF) enhances breast cancer cell motility by mobilising ERK1/2 phosphorylation and cytoskeletal rearrangement.
Taylor AP, Leon E, Goldenberg DM
Br J Cancer 2010 Jun 29, 103:82-9
 [PubMed Central] [PubMed] [Related articles]

This article is also cited by 1 article in BioMed Central


You can also check ISI Web of Science for additional citations (subscription required)
printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.